- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00835185
Study of IMC-11F8 in Participants With Colorectal Cancer
December 21, 2015 updated by: Eli Lilly and Company
Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer
The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the anti-tumor activity (best overall response) of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody IMC-11F8 administered in combination with mFOLFOX-6 chemotherapy regimen in treatment-naive, locally-advanced or metastatic CRC participants.
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically-confirmed, EGFR-detectable or EGFR-undetectable CRC
- Locally-advanced unresectable or metastatic adenocarcinoma of the colon or rectum
- At least 1 unidimensional-measurable target lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI); target lesion(s) must not lie within an irradiated area
- Age ≥18 years
- Life expectancy of ≥6 months
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2 at study entry
- Adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) ≥1.5 x 10^9 liter (L), hemoglobin ≥10 grams per deciliter (g/dL), and platelets ≥100 x 10^9/L
- Adequate hepatic function as defined by a total bilirubin ≤1.5 milligrams per deciliter (mg/dL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN) (or 5.0 x ULN in the case of liver metastases), and alkaline phosphatase (AP) ≤2.5 x ULN (or 5.0 x ULN in the case of liver metastases)
- Adequate renal function as defined by a serum creatinine ≤1.5 x ULN, creatinine clearance ≥ 60 milliliters per minute (mL/min), or serum albumin ≥lower limit of normal (LLN)
- Participant's relevant toxicities/effects of prior therapy [surgery/radiation therapy (RT)] must have recovered to a stable or chronic level
- Participant agrees to use adequate contraception during the study period and for 4 weeks after the last dose of study treatment. Participants must notify the principal investigator if they themselves or their partner becomes pregnant.
- Participant has provided signed Informed Consent
Exclusion Criteria:
- Has received prior systemic chemotherapy for locally-advanced unresectable or metastatic CRC.
- Has received prior radiotherapy to >25% of bone marrow
- Has documented and/or symptomatic brain metastases
- Has participated in clinical studies of non-approved experimental agents or procedures within 12 weeks of study entry
- Has received previous therapy with monoclonal antibodies
- Has received previous therapy with any agent that targets the EGFR
- Has serious concomitant medical conditions including active uncontrolled infection or cardiac disease, which in the opinion of the investigator, could compromise the participant or study.
- On chronic non-topical corticosteroid treatment for >6 months at doses >10 milligrams per day (mg/day) of prednisolone or equivalent before study entry, which in the opinion of the investigator could compromise the participant or the study
- Has a known dihydropyrimidine dehydrogenase deficiency
- Has a known allergy to any of the treatment components
- Has an acute or subacute intestinal occlusion
- Has peripheral neuropathy ≥Grade 2
- Has a history of other malignancies, with the exception of curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix
- If female, is pregnant (confirmed by urine or serum beta human chorionic gonadotropin test) or breast-feeding
- Has received a prior autologous or allogeneic organ or tissue transplantation
- Has interstitial pneumonia or interstitial fibrosis of the lung
- Has pleural effusion or ascites that causes ≥Grade 2 dyspnea
- Has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of Informed Consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IMC-11F8 (necitumumab) /mFOLFOX-6 regimen
Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
|
IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
Other Names:
Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
FA 400 mg/m² IV infusion bolus injection
5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )
Time Frame: Up to 30 Months
|
CR and PR defined using Response Evaluation Criteria In Solid Tumors (RECIST) version (v) 1.0 criteria.
CR was defined as the disappearance of all target and non-target lesions and PR defined as a ≥30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD.
Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence) / (total number of participants treated) * 100.
|
Up to 30 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: First dose to date of death from any cause up to 30 months
|
OS was defined as the duration from the date of first dose to the date of death from any cause.
OS was estimated by the Kaplan-Meier method.
Participants who were alive at the time of the data inclusion cutoff or lost to follow-up, OS was censored at the last contact.
|
First dose to date of death from any cause up to 30 months
|
Progression-Free Survival (PFS)
Time Frame: First dose to measured PD or death up to 30 months
|
PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause.
Progressive disease (PD) was determined using RECIST v1.0 criteria.
PD was defined as ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of new lesions and/or unequivocal progression of existing nontarget lesions.
PFS was estimated by the Kaplan-Meier method.
Participants who had no PD or death at the time of the data inclusion cutoff, PFS was censored at their last tumor assessment prior to the earliest of the following events: 2 or more missed visits, additional cancer treatment or the end of the follow-up period.
|
First dose to measured PD or death up to 30 months
|
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs) or Death
Time Frame: First dose to end of treatment and 30-day post treatment follow-up up to 31 months
|
The number of participants who experienced AEs, SAEs or death during the study and within 30 days of last dose.
A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
|
First dose to end of treatment and 30-day post treatment follow-up up to 31 months
|
Duration of Response
Time Frame: Time of response to time of measured PD or death up to 30 months
|
The duration of response was defined as the time from first confirmed CR or PR to the first time of PD or death due to any cause.
CR, PR and PD were defined using RECIST v1.0 criteria.
CR was defined as the disappearance of all target and non-target lesions; PR was defined as a ≥30% decrease in the sum of the LD of the target lesions, taking as reference the baseline sum of the LD; PD was defined as a ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of new lesions and/or unequivocal progression of existing nontarget lesions.
Participants with CR or PR who had no PD or death at the time of the data inclusion cutoff, the duration of response was censored at their last contact.
|
Time of response to time of measured PD or death up to 30 months
|
Serum Anti-IMC-11F8 Antibody Assessment (Immunogenicity)
Time Frame: Baseline up to last day of treatment plus 45 days after last treatment (127 weeks)
|
A participant was considered to have an anti-IMC-11F8 response if there were 2 consecutive positive samples or if the final sample tested is positive.
Participants with a baseline sample positive for anti-IMC-11F8 antibodies were considered unevaluable for immunogenicity.
A sample was considered positive for IMC-11F8 antibodies if it exhibited a post-baseline treatment emergent antibody level that exceeded the upper 95% confidence interval of the mean determined from the normal anti-IMC 11F8 level found in healthy treatment-naïve individuals.
|
Baseline up to last day of treatment plus 45 days after last treatment (127 weeks)
|
Maximum Concentration (Cmax) of IMC-11F8 at Study Day 1 of Cycle 1
Time Frame: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
|
Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of IMC-11F8 at Study Day 1 of Cycle 1
Time Frame: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
|
Half-Life (t1/2) of IMC-11F8 at Study Day 1 of Cycle 1
Time Frame: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
The t1/2 is the time measured for the plasma concentration of the drug to decrease by one half.
|
Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
Clearance (CL) of IMC-11F8 at Study Day 1 of Cycle 1
Time Frame: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
CL is the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time.
|
Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
Volume of Distribution (Vss) of IMC-11F8 at Study Day 1 of Cycle 1
Time Frame: Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug at steady-state.
|
Cycle 1 Day 1 predose, immediately after infusion, and 1, 2, 4, 24, 72, 96, 144, 168 and 236 hours postdose
|
Cmax at Study Day 1 of Cycles 2 Through 6
Time Frame: Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
|
Area Under the Curve (AUC) at Study Day 1 of Cycles 2 Through 6
Time Frame: Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
|
t1/2 at Study Day 1 of Cycles 2 Through 6
Time Frame: Day 1 Cycles 2 through 6 predose and 1 hour post dose
|
Day 1 Cycles 2 through 6 predose and 1 hour post dose
|
|
CL at Study Day 1 of Cycles 2 Through 6
Time Frame: Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
|
Vss at Study Day 1 of Cycles 2 Through 6
Time Frame: Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
Day 1 Cycles 2 through 6 predose and 1 hour postdose
|
|
Change From Baseline in Tumor Size
Time Frame: Baseline, 29 Months
|
Baseline, 29 Months
|
|
Kirsten Rat Sarcoma (KRAS) Mutation Status
Time Frame: Baseline
|
Tumor tissues collected prior to study drug administration were evaluated for the presence or absence of KRAS mutations by a retrospective analysis.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2007
Primary Completion (ACTUAL)
January 1, 2010
Study Completion (ACTUAL)
October 1, 2010
Study Registration Dates
First Submitted
February 2, 2009
First Submitted That Met QC Criteria
February 2, 2009
First Posted (ESTIMATE)
February 3, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
January 29, 2016
Last Update Submitted That Met QC Criteria
December 21, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Protective Agents
- Antineoplastic Agents, Immunological
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Hematinics
- Oxaliplatin
- Leucovorin
- Levoleucovorin
- Antibodies, Monoclonal
- Folic Acid
- Necitumumab
Other Study ID Numbers
- 13926
- 2006-003147-23 (EUDRACT_NUMBER)
- CP11-0602 (OTHER: ImClone Systems)
- I4X-IE-JFCD (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
Clinical Trials on IMC-11F8 (necitumumab)
-
Eli Lilly and CompanyCompletedSolid TumorsNetherlands
-
Eli Lilly and CompanyCompletedSolid TumorsUnited States
-
Eli Lilly and CompanySCRI Development Innovations, LLCTerminatedNon-small Cell Lung Cancer MetastaticUnited States
-
Eli Lilly and CompanyParexelCompleted
-
Eli Lilly and CompanyUniversity of Colorado, Denver; PPD; Parexel; ICON Clinical Research; Laboratory... and other collaboratorsActive, not recruitingNon Small Cell Lung CancerUnited States, Belgium, Brazil, Russian Federation, Serbia, Spain, United Kingdom, Germany, Australia, Hungary, Italy, Romania, Austria, Croatia, France, Greece, Poland, Portugal, Slovakia, South Africa, Philippines, Canada, Korea,... and more
-
Eli Lilly and CompanyCompletedSquamous Non Small Cell Lung CancerUnited States, Germany, Poland, Mexico, Korea, Republic of, Russian Federation
-
Eli Lilly and CompanyCelgeneCompletedCarcinoma, Non-Small Cell Lung Cancer (NSCLC)United States
-
Eli Lilly and CompanyUniversity of Colorado, Denver; Quintiles, Inc.; PPD; Parexel; Laboratory Corporation... and other collaboratorsCompletedNon Small Cell Lung CancerBelgium, Brazil, Russian Federation, United Kingdom, Australia, Germany, Hungary, Italy, Romania, United States, Austria, Canada, Croatia, France, Greece, Poland, Portugal, Slovakia, South Africa, Spain
-
Eli Lilly and CompanyCompletedSquamous Non-small Cell Lung CancerJapan
-
Eli Lilly and CompanyCompletedNon-small Cell Lung CancerSpain, France, United States, Taiwan, Canada, Netherlands, Mexico